Hjalmar Flygt

Hjalmar Flygt (MD, PhD) is a specialist physician with broad experience in internal medicine, currently specializing in hematology. Clinically, he works with benign and malignant hematological diseases and bone marrow transplantations.
Hjalmar’s research aims explore the myeloproliferative disorders (MPN) and the Philadelphia chromosome-positive diseases chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) from a epidemiological and genetic perspective.
He has been a CTC associate since 2019 and has served as principal investigator and sub-investigator in more than 30 early-phase clinical trials.

Latest publications

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial - PubMed 26 January, 2024

The impact of Covid-19 in patients with chronic myeloid leukemia-a nationwide population-based study - PubMed 10 April, 2023

Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study 11 January, 2022

Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study 21 August, 2021

Successful tyrosine kinase inhibitor discontinuation outside clinical trials – data from the population-based Swedish chronic myeloid leukaemia registry 30 March, 2021

Neurosurgical untethering with or without syrinx drainage results in high patient satisfaction and favorable clinical outcome in post-traumatic myelopathy patients 29 March, 2018

We provide our customers with cost-effective advice, conduct and reporting of clinical trials.

Contact us